COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [1] A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC)
    Panje, Cedric M.
    Dedes, Konstantin J.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Gautschi, Oliver
    Siano, Marco
    Aebersold, Daniel M.
    Plasswilm, Ludwig
    Lupatsch, Judith E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 129 (02) : 257 - 263
  • [2] Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients
    Gilden, Daniel M.
    Kubisiak, Joanna M.
    Pohl, Gerhardt M.
    Ball, Daniel E.
    Gilden, David E.
    John, William J.
    Wetmore, Stewart
    Winfree, Katherine B.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 151 - 161
  • [3] Efficiency of nivolumab in the treatment of second-line advanced non-squamous non-small cell lung cancer (NSCLC) in Spain
    Gonzalez, P.
    Ortega-Joaquin, N.
    Provencio Pulla, M.
    Garrido, C.
    Echave, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [4] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [6] Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data
    Chaudhary, Mohammad A.
    Holmberg, Christoffer
    Lakhdari, Khalid
    Smare, Caitlin
    Theriou, Chloi
    Dale, Peter
    Penrod, John R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 607 - 619
  • [7] Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Aebi, Stefan
    Dedes, Konstantin
    Diebold, Joachim
    Pietrini, Mario
    Klingbiel, Dirk
    Von Moos, Roger
    Gautschi, Oliver
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1430 - S1431
  • [8] Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC)
    Tassinari, D.
    Drudi, F.
    Carloni, F.
    Nicoletti, S.
    Possenti, C.
    Santelmo, C.
    Lazzari, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the US
    Kumar, Gayathri
    Woods, Beth
    Hess, Lisa M.
    Treat, Joseph
    Boye, Mark E.
    Bryden, Peter
    Winfree, Katherine B.
    [J]. LUNG CANCER, 2015, 89 (03) : 294 - 300
  • [10] Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer
    Crino, Lucio
    Bronte, Giuseppe
    Bidoli, Paolo
    Cravero, Paola
    Minenza, Elisa
    Cortesi, Enrico
    Garassino, Marina C.
    Proto, Claudia
    Cappuzzo, Federico
    Grossi, Francesco
    Tonini, Giuseppe
    Sarobba, Maria Giuseppina
    Pinotti, Graziella
    Numico, Gianmauro
    Samaritani, Riccardo
    Ciuffreda, Libero
    Frassoldati, Antonio
    Bregni, Marco
    Santo, Antonio
    Piantedosi, Francovito
    Illiano, Alfonso
    De Marinis, Filippo
    Tamberi, Stefano
    Giannarelli, Diana
    Delmonte, Angelo
    [J]. LUNG CANCER, 2019, 129 : 35 - 40
12345